ovarian cancer
Research identifies marker for aggressive ovarian cancer
April 26, 2017Research and Development Cancer, ovarian cancer
Scientists have identified a marker which they believe can inform whether a tumour will become more aggressive and pose a …
Investigational ImmunoGen drug gives hope against platinum-resistant ovarian cancer
April 20, 2017Research and Development Cancer, Immunogen, ovarian cancer
Research from GlobalData has suggested that an investigational drug from ImmunoGen could prove effective in treating platinum-resistant ovarian cancer, an …
J&J pays $70m over cancer allegations
October 28, 2016Medical Communications JJohnson & Johnson, ovarian cancer
Johnson & Johnson has been forced to pay out $70 million after it was alleged that years of using the …
AZ withdraws European filing for ovarian cancer therapy
September 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, cediranib, ovarian cancer
AstraZeneca is no longer seeker European approval for its oral multi-VEGF receptor inhibitor cediranib for treatment of ovarian cancer after withdrawing …
Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer
August 25, 2016Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib
Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …
Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump
June 30, 2016Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer
Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …
AstraZeneca says latest study data for Lynparza suggest improvement in overall survival in ovarian cancer
June 7, 2016Manufacturing and Production, Research and Development, Sales and Marketing ASCO, AstraZeneca, NHS, lynparza, ovarian cancer, regulation
UK drugmaker AstraZeneca (LSE: AZN) said mid-stage trials for Lynparza (olaparib) maintenance therapy suggest an improvement in overall survival (OS) …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
Clinical trials initiated for novel immunotherapy combo for ovarian cancer
April 7, 2016Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx
A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …
Pfizer, Merck and Syndax in ovarian cancer trial collaboration
January 5, 2016Manufacturing and Production, Research and Development Merck, Pfizer, Syndax Pharmaceuticals, avelumab, entinostat, ovarian cancer
Pfizer, Merck and Syndax Pharmaceuticals have announced a collaboration to test avelumab, in combination with Syndax’s entinostat, in patients with …
Merck and Pfizer kick off Phase III avelumab cancer trials
December 23, 2015Research and Development Merck, Pfizer, avelumab, ovarian cancer
Merck and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
New treatment option for ovarian cancer patients in Scotland
September 8, 2015Medical Communications, Research and Development, Sales and Marketing Roche, Scotland, avastin, ovarian cancer
The Scottish Medicines Consortium (SMC) has approved the use of Avastin in combination with paclitaxel chemotherapy as a treatment for women …
NICE demands more evidence of Lynparza benefits
August 6, 2015Sales and Marketing AstraZeneca, NICE, lynparza, ovarian cancer
AstraZeneca must provide a “robust estimate of the cost effectiveness” of its ovarian cancer treatment Lynparza, or risk being rejected …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
